Compass shares rose 3% after the London-based mental-health care group reported in a follow-up study that its COMP360 psilocybin treatment, alongside psychological support, led to remission of depression in most cancer patients.
Read Full Story
Latest posts by Market Watch (see all)
- Help My Career: Younger workers know being remote has drawbacks, but they don’t care. Here’s why. - June 5, 2023
- The Tell: Here’s the pain trade Citi sees in U.S. stocks as S&P 500 exceeds its 2023 target - June 5, 2023
- : Is it worth spending $3,499 on Apple’s Vision Pro VR headset? Read this first. - June 5, 2023
